Zelira Therapeutics Management
Management criteria checks 3/4
Zelira Therapeutics' CEO is Oludare Odumosu, appointed in Jan 2021, has a tenure of 3.92 years. total yearly compensation is A$557.33K, comprised of 81% salary and 19% bonuses, including company stock and options. directly owns 1.16% of the company’s shares, worth A$75.11K. The average tenure of the management team and the board of directors is 5 years and 5 years respectively.
Key information
Oludare Odumosu
Chief executive officer
AU$557.3k
Total compensation
| CEO salary percentage | 81.0% |
| CEO tenure | 3.9yrs |
| CEO ownership | 1.2% |
| Management average tenure | 5yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 08
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?
Jul 14Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely
Jan 19Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Sep 25Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Jun 03A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
Dec 31
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$557k | AU$451k | -AU$37m |
| Mar 31 2024 | n/a | n/a | -AU$36m |
| Dec 31 2023 | n/a | n/a | -AU$36m |
| Sep 30 2023 | n/a | n/a | -AU$21m |
| Jun 30 2023 | AU$479k | AU$445k | -AU$6m |
| Mar 31 2023 | n/a | n/a | -AU$8m |
| Dec 31 2022 | n/a | n/a | -AU$10m |
| Sep 30 2022 | n/a | n/a | -AU$11m |
| Jun 30 2022 | AU$642k | AU$449k | -AU$12m |
| Mar 31 2022 | n/a | n/a | -AU$11m |
| Dec 31 2021 | n/a | n/a | -AU$10m |
| Sep 30 2021 | n/a | n/a | -AU$9m |
| Jun 30 2021 | AU$560k | AU$318k | -AU$9m |
| Mar 31 2021 | n/a | n/a | -AU$8m |
| Dec 31 2020 | n/a | n/a | -AU$8m |
| Sep 30 2020 | n/a | n/a | -AU$8m |
| Jun 30 2020 | AU$321k | AU$114k | -AU$7m |
Compensation vs Market: Oludare's total compensation ($USD347.46K) is about average for companies of similar size in the Australian market ($USD289.50K).
Compensation vs Earnings: Oludare's compensation has increased whilst the company is unprofitable.
CEO
Oludare Odumosu
3.9yrs
Tenure
AU$557,327
Compensation
Dr. Oludare Odumosu serves as Director of Zelira Therapeutics Limited (formerly Zelda Therapeutics Ltd) since December 02, 2019. He serves as the Managing Director & Global Chief Executive Officer of Zelir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 5yrs | AU$151.31k | 3.78% A$ 244.5k | |
| MD, Global CEO & Director | 3.9yrs | AU$557.33k | 1.16% A$ 75.1k | |
| Executive Director | no data | AU$323.02k | no data | |
| Company Secretary & Non-Executive Director | 8.2yrs | AU$65.18k | 0.069% A$ 4.5k | |
| Vice President of Finance & Accounting | no data | no data | no data | |
| Clinical Trial Consultant | no data | no data | no data |
5.0yrs
Average Tenure
Experienced Management: ZLD's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 5yrs | AU$151.31k | 3.78% A$ 244.5k | |
| MD, Global CEO & Director | 5yrs | AU$557.33k | 1.16% A$ 75.1k | |
| Executive Director | 1.8yrs | AU$323.02k | no data | |
| Company Secretary & Non-Executive Director | 2.9yrs | AU$65.18k | 0.069% A$ 4.5k | |
| Member of Medical Advisory Board | no data | AU$12.00k | 2.22% A$ 143.8k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 8.8yrs | no data | no data | |
| Member of Medical Advisory Board | 8.8yrs | no data | no data | |
| Scientific & Medical Advisory Board | 6.3yrs | no data | no data | |
| Scientific & Medical Advisory Board | 6.3yrs | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | AU$105.76k | no data |
5.0yrs
Average Tenure
Experienced Board: ZLD's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:03 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zelira Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ryan Hampton | Hannam & Partners (Advisory) LLP |